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Abstract 
 
Aims  
Cardiovascular disease (CVD) is a major cause of morbidity and mortality worldwide, 
particularly in individuals with diabetes. The prediction of CVD risk among diabetics is 
therefore important in disease management. The aim of the current study was to determine the 
circulating metabolite profiles associated with the risk of future cardiovascular events, with 
emphasis on the diabetes status of the participants.  
 
Methods and Results  
Non-targeted metabolomics analysis was performed by high-resolution mass spectrometry in 
combination with targeted quantification of eicosanoids and endocannabinoids. A total of 375 
individuals from the IMPROVE pan-European cohort were included. Following data 
processing, the three metabolite datasets were concatenated to produce a single dataset of 270 
identified metabolites. Factor analysis identified six factors that described 26.6% of the total 
variability in the given set of predictors. A significant association with cardiovascular events 
was only observed for one factor following adjustment (p=0.026). From this factor, we 
identified a free fatty acid signature (n=10 lipids, including saturated, monounsaturated, and 
polyunsaturated fatty acids) that was associated with lower risk of future cardiovascular 
events in non-diabetics only (OR=0.65, p=0.03), whereas no association was observed among 
diabetic individuals. A similar trend was observed in Cox proportional hazard regression, with 
free fatty acids associating with longer time to incident cardiovascular events in only the non-
diabetic group (HR=0.80, p=0.024). 
 
Conclusions  
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Increased levels of circulating omega-6 and omega-3 fatty acids are associated with protective 
effects against future cardiovascular events. However, these effects were only observed in the 
non-diabetic population, further highlighting the need for stratification in clinical 
investigations.  
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Translational Perspective (100 words max) 
Recent reports have identified elevated plasma levels of omega 6 and omega 3 fatty acids as 
having protective effects for future cardiovascular events. Using a ?3-year? follow-up study of 
high-risk European subjects, our results  corroborate these findings in patients without 
diabetes, but we report that the observed protective effects were not seen  in those with 
diabetes at baseline. This demonstrates the need to stratify patients  by diabetic status in order 
to present accurate future risk information. Importantly, these data indicate that any 
recommendations concerning the potential protective effects of dietary fat vary with diabetic 
status.  
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Introduction  
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide (1), 
and is especially pronounced amongst individuals with diabetes (2). While multiple potential 
markers have been proposed for predicting future cardiovascular events, there is significant 
uncertainty regarding their ability to accurately predict risk (3). Metabolomics has been 
successfully applied to determine the circulating metabolic profile in an effort to link specific 
metabolites to the onset of CVD (4-7) and diabetes (8, 9). A recent large prospective study of 
3 population-based cohorts employed high-throughput NMR-based metabolomics, in 
combination with a targeted metabolomics platform, to identify (sets of) biomarkers that 
improved CVD risk prediction (7). In the current study, we have applied non-targeted high-
resolution mass spectrometry to determine the metabolite profiles associated with the risk of 
future cardiovascular events. These metabolomics studies were complemented with targeted 
analyses of eicosanoids and endocannabinoids, which have known roles in CVD as well as 
diabetes (10). We placed particular focus on the effect of diabetic status upon the reported 
biomarkers within the framework of the SUrrogate markers for Micro- and Macro-vascular 
hard endpoints for Innovative diabetes Tools (SUMMIT) consortium (11), which aimed to 
identify and characterize biomarkers for complications of diabetes.  
 
Methods 
Methods including statistical analyses are described in the online data supplement. The study 
design and participant inclusion and matching criteria are provided in Figure S1. 
 
Results 
The baseline characteristics of the study population according to the presence of diabetes are 
summarized in Table S1. Among both diabetics and non-diabetics, the cases showed less 
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favorable anthropometric and metabolic profiles, and used more medication compared to the 
controls. Case-control differences were accentuated among the individuals with diabetes.  
Following data processing, the non-targeted metabolomics profiling yielded 1978 
unique features, of which 270 were matched to chemical reference standards by accurate mass 
and retention time. Of the 270 metabolites, 50 had >25% of the values below the limit of 
detection. These compounds were excluded to give 220 identified metabolites. The remaining 
1708 features were annotated putatively. A total of 104 lipid mediators from the eicosanoid 
and endocannabinoid platforms were screened, of which 50 compounds were present above 
the limit of quantification. These lipid mediators are generally present at concentrations too 
low to be detected by metabolomics, and were therefore quantified using targeted methods. 
The metabolomics and lipid mediator datasets were concatenated to produce a single dataset 
of 270 metabolites included in the analyses described below. 
Analysis of the scree plot showed that six factors had eigenvalues greater than the 
average eigenvalue (Figure S2). Accordingly, six factors were retained after the varimax 
orthogonal rotation for the primary analysis. The six factors described 26.6% of the total 
variability in the given set of predictors (Table S2 for a description of components for each of 
the selected factors). Amongst the diabetics, there was no significant association between any 
of the six factors and cardiovascular events (Table S3). In non-diabetics, two of the factors 
were significantly associated with cardiovascular events at p<0.05. Following adjustment for 
BMI, hypertension, HDL-cholesterol and anti-platelet medication, only Factor 1 (F1) 
remained significant (p=0.026). F1 contained 39 metabolites (Figure S3), the majority of 
which were free fatty acids (n=10, Figure 1) or their downstream metabolic products (e.g., 
eicosanoids [n=19] and endocannabinoids [n=5]). The free fatty acids in F1 included 
polyunsaturated (PUFAs), monounsaturated (MUFAs) and saturated fatty acids (SAT) (Figure 
S4). In non-diabetics, high concentrations of free fatty acids were associated with lower odds 
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to suffer cardiovascular events (OR between 0.27 and 0.80), whereas no association was 
observed among diabetic individuals (Figure 1). A similar trend was observed in Cox 
proportional hazard regression for the F1 free fatty acids. F1 associated with longer time to 
incident cardiovascular events in the non-diabetic group (HR=0.80, p=0.024) (Table S4). All 
free fatty acids measured were associated with a protective effect in non-diabetic individuals.  
In the non-diabetic group, pairwise Spearman rank correlation analysis between the 
six selected metabolic factors and cIMT measurements identified an association between 
Factor 2 and all IMT readouts at baseline, as well as baseline ICCAD, which disappeared after 
adjusting for age, gender and MDS1. Also in non-diabetics, a significant inverse correlation 
was observed between Factor 3 and progression of Bulb-IMTmean (r=-0.23, p= 0.002), which 
disappeared after further adjustments for cardiovascular risk factors and medication (β=-
0.011, p=0.067). Associations between F1 and cIMT variables were essentially non-
significant. However, a significant correlation was found between F1 and ICCAD change 
over time in non-diabetes, tested in linear regression with adjustment for MDS1, 
cardiovascular risk factors (hypertension, blood glucose, ever smoking) and medication (lipid-
lowering drugs, angiotensin II receptor blockers and anti-platelets) (β=-0.008, p=0.001) 
(Table S5). To identify the major effects for association with ICCAD change over time among 
metabolites included in F1, we ran linear regression analysis for each component (Table S6). 
The strongest association was observed with linoleic acid-derived metabolites, including: 
12(13)-epoxy octadecanoic acid (EpOME; β=-0.018, p=0.001), 9- and 13-
hydroxyoctadecadienoic acid (9-HODE and 13-HODE; β=-0.017, p=0.002 and β=-0.018, 
p=0.001, respectively), as well as 13-keto octadecadienoic acid (13-KODE; β=-0.014, 
p=0.002). Another group of interesting compounds associated with the dynamics of ICCAD 
were N-stearoyl taurine (β=-0.008, p=0.001) and N-palmitoyl taurine (β=-0.011, p=0.009). 
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Discussion 
In the present report, non-targeted metabolomics analyses of plasma from a subset of the 
IMPROVE cohort identified in non-diabetic subjects a signature of free fatty acids associated 
with lower risk of future cardiovascular events. These observations corroborate the results 
recently reported by Würtz et al. (7) in a large prospective discovery cohort of 7,256 
individuals, replicated in two other cohorts of 2,622 and 3,563 individuals. The two studies 
had similar objectives; however, Würtz et al. did not directly examine the effect of diabetes. 
The IMPROVE study recruited subjects at high-risk of CVD, resulting in a cohort with 
elderly participants (mean age 64 years) and 30% prevalence of diabetes. Based upon the high 
prevalence of diabetes, and within the framework of the SUMMIT consortium, our analyses 
were stratified by diabetes status. We observed that the risk for future cardiovascular events 
differed significantly between the two strata, and that omega-6 fatty acids were significantly 
associated with lower risk of future cardiovascular events only in non-diabetics. Würtz et al 
(7) identified omega-6 fatty acids to be significantly associated with lower risk of future 
cardiovascular events (HR=0.89) over 15 years of follow-up in a large population with a 
lower diabetes prevalence (~7.8%), which potentially explains the lack of reported diabetes-
related differences.  
We also found that circulating levels of MUFAs, herein represented by palmitoleic, 
oleic, and mead acids, were associated with lower risk of cardiovascular events in non-
diabetic individuals. This finding agrees with earlier reports in which dietary MUFAs were 
shown to directly correlate with the circulating levels (12), and with a favorable lipoprotein 
profile and thus lower risk of CVD (13). By contrast, Würtz et al reported that increased 
levels of MUFAs were associated with a slightly higher risk for cardiovascular events 
(HR=1.17). The protective effect that we observed in relation to increased levels of circulating 
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fatty acids is not restricted to one type of fatty acid, but includes PUFAs, MUFAs and SATs, 
with both omega-6 and omega-3 fatty acids.  
Although not a primary goal, we also analyzed the relationships between 
metabolomics factors and carotid artery ultrasound measurements taken in the participants at 
the baseline and in progression over 3 years of follow-up. Measurement of cIMT is a non-
invasive way of assessing atherosclerosis, shown to be strongly associated with asymptomatic 
early stage of the process (14). In the original IMPROVE study, the progression of the 
maximum IMT detected after 15 months in the whole carotid tree, regardless of location 
(Fastest-IMT(max-progr)), was significantly associated with the risk of subsequent vascular 
events, whereas none of the other cIMT measures showed predictive value (15). In the present 
study, the only significant association found was between F1 and lower change over time in 
ICCAD in non-diabetics. ICCAD measured in plaque free areas is assumed to reflect carotid 
expansion due to atherosclerosis and correlates with several vascular risk factors. 
Interestingly, the protective associations between F1 and change in ICCAD were driven by 
metabolic products of linoleic acid (12[13]-EpOME and 9[10]-EpOME, 9-HODE, 13-HODE 
and 13-KODE) and taurine derivatives (N-stearoyl taurine and N-palmitoyl taurine). The data 
on linoleic acid (and its derivatives) are unclear, but a recent meta-analysis reported a 
suggestive relationship between dietary linoleic acid and diabetes as well as CVD (16). 
Taurine, an abundant amino acid-like compound distributed throughout human tissues, has a 
long list of biological activity, including atheroprotective, anti-inflammatory and anti-obesity 
effects (17, 18). Taurine has also been studied in relation to cardiovascular prevention and 
obesity, although the effects of taurine ingestion in humans remain unclear (17, 18). The 
metabolic effects of palmitic and stearic conjugates have not been well studied and are 
unclear in the current context.  
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All participants of the present study were Europeans, which, to some extent, 
precludes generalization of the observations to other populations. Another limitation is the 
relatively small size, particularly of the diabetes subset, and lack of a replication cohort. 
However, the data confirms previous similar results in larger studies (7), and moreover  
generates the hypothesis that those findings are not applicable to entire populations. The lack 
of protective effects observed for any of the measured fatty acids with respect to occurrence 
of cardiovascular events among diabetic participants, calls for further studies into the 
increased CVD risk in these patients.  
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Figure 1. Association of the free fatty acids within Factor 1 with incidence of 
cardiovascular events stratified by diabetes status. Factor analysis of the n=270 
metabolites from the concatenated metabolomics, eicosanoid and endocannabinoid datasets 
identified six factors that described 26.6% of the total variability in the given set of predictors 
(Table S2). Following adjustment for BMI, hypertension, HDL cholesterol and anti-platelet 
medication, only Factor 1 (F1) remained significant (p=0.026). F1 contained 39 metabolites 
(Figure S3), the majority of which were free fatty acids (n=10) or their downstream metabolic 
products (e.g., eicosanoids [n=19], endocannabinoids [n=5]). Stratification by diabetic status 
showed that, high concentrations of free fatty acids were only associated with lower odds to 
suffer cardiovascular events in non-diabetics (OR between 0.27 and 0.80). No association was 
observed among diabetic individuals. Linoleic acid was manually added given its relevance to 
CVD, even though the loadings were below the <0.4 cutoff. 
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